Atopic Dermatitis
Atopic Dermatitis (AD), also known as atopic eczema, is a common, chronic inflammatory skin condition characterized by itchy, red, swollen, and cracked skin, sometimes oozing clear fluid, that may thicken over time. Treatment typically addresses inflammation, itching, and the disrupted skin barrier.
Health Outcomes
- Absence of Deep Epithelial Disruption
- Accelerated Immune Response Maturation
- Accelerated Oral Tolerance Development
- Alleviated Clinical Symptoms of Atopic Dermatitis
- Altered Chemokine Response
- Altered Dominant Microbial Community
- Altered Epithelial Plasma Membrane Properties
- Altered IL-4 Levels
- Altered Microbial Composition
- Altered Microbial Population Composition
- Altered T Cell Migratory Behavior
- Altered TH1/TH2 Immune Response
- Clinical Remission of Atopic Dermatitis
- Cosmetic Material Identification
- Elevated Ceramide Levels in Skin
- Elevated Serum IgE Levels
- Elevated Serum Total Ig Levels
- Enhanced Barrier Integrity
- Enhanced Cytokine Production
- Enhanced Epithelial Cell Defense Functions
- Enhanced Epithelial Cell Migration
- Enhanced Host-Microbe Balance
- Enhanced Immune Response (Higher IL-4 Levels)
- Enhanced Immune Response to Gram-Positive Bacteria
- Enhanced Infant Gut Microbiota by Bifidobacterium lactis
- Enhanced Membrane Barrier Integrity
- Enhanced Phototherapy Outcome
- Enhanced Production of Natural Moisturizing Factor
- Enhanced Skin Gloss
- Enhanced Skin Mucosal Immune Parameters
- Enhanced Skin Mucus Protease Activity
- Enhanced Type 2 Helper T Cell Response
- Enhanced β-Defensin 3 Activity
- Good Tolerability
- Improved Allergic Immune Responses
- Improved Allergic Inflammation Markers
- Improved Allergic Outcomes
- Improved Allergic Symptoms
- Improved Allergy Effectiveness
- Improved Anti-Allergy-Related Cytokine Profile
- Improved Antiallergic Function
- Improved Antioxidant and Anti-Inflammatory Response
- Improved Atopic Dermatitis
- Improved Atopic Dermatitis Control Tool
- Improved Atopic Dermatitis Management
- Improved Atopic Dermatitis Severity
- Improved Barrier Integrity
- Improved Clinical Disease Activity
- Improved Clinical Remission
- Improved Cow's Milk Protein Tolerance Acquisition
- Improved Dermal Health Parameter
- Improved Dermatology Life Quality Index
- Improved Eczema Severity
- Improved Eczema Symptom
- Improved Eczema Symptoms
- Improved Epidermal Lipid Barrier Function
- Improved Epidermal Moisturization
- Improved Epithelial Barrier Function
- Improved Epithelial Barrier Integrity
- Improved Epithelial Integrity
- Improved Epithelial Protection
- Improved Facial Skin Hydration
- Improved Filaggrin Production
- Improved Global Assessment
- Improved Global Eczema Symptoms
- Improved Health in Children with Allergies
- Improved Hyperpigmentation Index
- Improved Illness Severity Status
- Improved Immune Balance
- Improved Immune Tolerance
- Improved Immunity Status
- Improved Immunoglobulin A Production
- Improved Immunoinflammatory Markers
- Improved Immunologic Barrier Function
- Improved Inflammatory Skin Condition
- Improved Interleukin-4 Levels
- Improved Investigator Global Assessment Score
- Improved Lesion Regression
- Improved Lipid Barrier Function
- Improved Microbial Structures
- Improved Moisture Content
- Improved Patient-Oriented Eczema Measure
- Improved Patient-Reported Outcome
- Improved Peanut Tolerance
- Improved Physician Global Assessment
- Improved Pruritus
- Improved Responder Rate
- Improved SCORAD Index
- Improved Scar Appearance
- Improved Skin Barrier Function
- Improved Skin Brightness
- Improved Skin Cell Proliferation
- Improved Skin Condition
- Improved Skin Condition Score
- Improved Skin Density
- Improved Skin Disease Severity
- Improved Skin Health
- Improved Skin Hydration
- Improved Skin Immunity
- Improved Skin Moisture Retention
- Improved Skin Mucus Lysozyme Activity
- Improved Skin Recovery
- Improved Skin Responses
- Improved Skin Symptoms
- Improved Symptom Severity
- Improved Symptom-Free Status
- Improved Symptoms
- Improved Th1/Th2 Balance
- Improved Th1/Th2 Ratio
- Improved Th17/Treg Ratio
- Improved Viability of Keratinocytes
- Increase in Bifidobacterium lactis HN019
- Increased Abundance of Bifidobacterium
- Increased Anti-inflammatory Cytokines
- Increased Antibody Secretion to Beta-Lactoglobulin
- Increased Antimicrobial Peptide LL-37 Level
- Increased Barrier-Preserving Protein Levels
- Increased Bifidobacteria Levels
- Increased Bifidobacterial Population
- Increased Bifidobacterium Proportion
- Increased Bifidobacterium longum Relative Abundance
- Increased Breast Milk Ovalbumin Level
- Increased Cathelicidin Level
- Increased Dendritic Cell Activation
- Increased Eosinophil Count
- Increased Epidermal Nerve Fiber Density
- Increased Expression of Antimicrobial Peptide Genes
- Increased Expression of Human Beta Defensin-2
- Increased Expressions of β-Defensins
- Increased Fractional Exhaled Nitric Oxide
- Increased Histamine Production
- Increased Host Defense Peptide Levels
- Increased IL-10 Levels
- Increased IL-17A Level
- Increased Immune Cell Activity
- Increased Immune Response
- Increased Immunoglobulin A (IgA)-Positive Cells
- Increased Immunoglobulin A Levels in Breast Milk
- Increased Immunoglobulin G Levels
- Increased Immunoglobulin G1 Levels
- Increased Indigenous Bifidobacterium Levels
- Increased Inflammatory Mediator Production
- Increased L. brevis-specific IgG Concentrations
- Increased LL-37 Levels
- Increased Levels of Actinobacteria
- Increased Levels of Bifidobacteria
- Increased Mast Cells in Mucosal Tissues
- Increased Natural Killer Cell Count
- Increased Nerve Growth Factor Level
- Increased Neutrophil Activity
- Increased OVA-specific IgG Levels Upon Immunization
- Increased Ovalbumin Level
- Increased Peanut Protein Eliciting Dose
- Increased Presence of Bifidobacterium lactis
- Increased Production of Anti-inflammatory Histamine
- Increased Production of Antimicrobial Peptides
- Increased Regulatory T Cell Frequency
- Increased Regulatory T Cell Response
- Increased Salivary IgA Levels
- Increased Secretory Immunoglobulin A Level
- Increased Serum Immunoglobulin Levels
- Increased Skin Hydration Level
- Increased Skin Mucus Antibacterial Activity
- Increased Skin Mucus IgG Levels
- Increased Skin Mucus Immune Response
- Increased Th2 Cytokines Production
- Increased Tolerance to Peanut Protein
- Increased Tolerated Peanut Dose
- Increased Tolerated Peanut Protein Dose
- Long-Lasting Immunomodulatory Effects After Weaning
- Maintained Barrier Function
- Maintained Beta-Defensin-2 Level
- Maintained Epithelial Barrier Integrity
- Maintained Epithelium Structure
- Maintained Remission of Skin Symptoms
- Modulated Eicosanoid Levels
- Modulated Systemic Th1/Th2 Balance
- No Adverse Effects
- No Change in Inflammatory or Anti-inflammatory Cytokine Levels
- No Clear Clinical Benefit
- No Improvement in Allergy Symptoms
- No Improvement in Apple Food Allergy Symptoms
- No Significant Change in IgE Levels
- No Significant Increase in Adverse Effects
- Potential Skin Effect
- Prevented Allergic Reactions
- Prevention and Treatment of Inflammatory Diseases
- Prevention of Aberrant Inflammatory Response
- Prevention or Treatment of Allergic Skin Disorders
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Reduced 12-Month Prevalence of Eczema at Age 11 Years
- Reduced Abundance of Pro-inflammatory Bacteria
- Reduced Activation of CD63 Expressing Basophils
- Reduced Adhesion of Streptococcus pyogenes to Human Cells
- Reduced Airway T Helper Type 2 Cytokines
- Reduced Allergen Hyperreactivity
- Reduced Allergen-Induced Skin Inflammation
- Reduced Allergic Dermatitis
- Reduced Allergic Diseases
- Reduced Allergic Disorders
- Reduced Allergic Inflammatory Response
- Reduced Allergic Markers
- Reduced Allergic Reaction Risk
- Reduced Allergic Reactions
- Reduced Allergic Responses
- Reduced Allergic Scores
- Reduced Allergic Symptom Score
- Reduced Allergic Symptoms
- Reduced Antigen-Specific IgE Levels
- Reduced Apoptotic Shedding of Epithelial Cells
- Reduced Atopic Dermatitis Medication Use
- Reduced Atopic Diseases
- Reduced Atopic Eczema
- Reduced Beta-Defensin Level
- Reduced Bifidobacterium Counts
- Reduced Bifidobacterium longum
- Reduced Ceramide Production
- Reduced Colony Colonization by Pathogenic Organisms
- Reduced Corticosteroid Use
- Reduced Dermal Irritation
- Reduced Dermal Mast Cell Infiltration
- Reduced Disease Activity
- Reduced Disruption of Normal Activities Due to Allergies
- Reduced Dryness Frequency
- Reduced Eczema
- Reduced Eczema Area and Severity Index
- Reduced Eczema Incidence
- Reduced Eczema Morbidity
- Reduced Eczema Prevalence
- Reduced Eczema Severity
- Reduced Eczema Symptoms
- Reduced Egg Allergy
- Reduced Egg White Sensitization
- Reduced Eosinophil Count
- Reduced Eosinophil Infiltration
- Reduced Eosinophilic Inflammation
- Reduced Epithelial Barrier Disruption
- Reduced Epithelial Breakdown
- Reduced Erythema Intensity
- Reduced Expression of CTACK
- Reduced Flare Area
- Reduced Food Allergy Incidence
- Reduced Food Allergy Symptom Severity
- Reduced Food Allergy Symptoms
- Reduced Food-Specific Immunoglobulin G4 Level
- Reduced HDM-Specific IgG1 Levels
- Reduced Histamine Release
- Reduced Hypersensitivity Responses
- Reduced IL-4 Levels
- Reduced IL-4 Secretion
- Reduced IL-4 Secretion from Naïve T Cells
- Reduced IL-5 Levels
- Reduced IL-8 Secretion
- Reduced IL-9 Levels
- Reduced IgE Levels
- Reduced IgE Production
- Reduced IgE-Associated Eczema in Infants
- Reduced Immunoglobulin E Production
- Reduced Incidence of Allergic Disorders
- Reduced Incidence of Allergic Manifestations
- Reduced Incidence of Atopic Dermatitis
- Reduced Incidence of Dermatitis
- Reduced Incidence of Milk Allergy
- Reduced Infant Allergies
- Reduced Infant Atopic Eczema and Allergic Disease
- Reduced Infant Eczema
- Reduced Infant Formula Switching
- Reduced Inflammation Markers
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammatory Activities
- Reduced Inflammatory Diseases
- Reduced Inflammatory Effects
- Reduced Inflammatory Factor Level
- Reduced Inflammatory Infiltrate
- Reduced Inflammatory Processes
- Reduced Inflammatory Response
- Reduced Inflammatory Stimulators
- Reduced Inflammatory Stress
- Reduced Interleukin-4 Levels
- Reduced Interleukin-4 Production
- Reduced Interleukin-5 Level
- Reduced Interleukin-8 Level
- Reduced Investigator Global Assessment
- Reduced Itch Severity
- Reduced Itching
- Reduced Itchy Nose
- Reduced Lesion Size
- Reduced Lifetime Prevalence of Atopic Sensitization
- Reduced Local Immunoglobulin Production
- Reduced Local Inflammation
- Reduced MAPK Activation
- Reduced Milk-Specific Immunoglobulin E Level
- Reduced OVA-Specific Antibodies
- Reduced Offspring Eczema Risk
- Reduced Ovalbumin-Specific IgE Level
- Reduced Ovalbumin-Specific IgE Production
- Reduced Overall Symptom Score
- Reduced Pathological Symptoms
- Reduced Peanut-Specific IgE Level
- Reduced Prevalence of Atopic Sensitization
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Profile from Cow Milk Formula
- Reduced Pruritus
- Reduced Pruritus Severity
- Reduced Rash Incidence
- Reduced Reaction Severity
- Reduced Risk of Colorectal Cancer
- Reduced Risk of Sensitization in Infants
- Reduced S. aureus Adhesion
- Reduced SARS-CoV-2 Infection
- Reduced SCORAD Index
- Reduced SCORAD Score
- Reduced Scalp Sebum Level
- Reduced Scratching Behavior
- Reduced Scratching Frequency
- Reduced Serum CTACK Levels
- Reduced Serum IgE Levels
- Reduced Serum Immunoglobulin E Levels
- Reduced Serum OVA-specific IgE Levels
- Reduced Skin Complication
- Reduced Skin Dryness Symptoms
- Reduced Skin Flakiness
- Reduced Skin Inflammation
- Reduced Skin Lesion Area
- Reduced Skin Oiliness
- Reduced Skin Redness
- Reduced Skin Surface Roughness
- Reduced Skin Water Loss
- Reduced Skin and Eye Irritation
- Reduced Squamous Cell Carcinoma
- Reduced Standard Care Medication Need
- Reduced Staphylococcal Infections
- Reduced Staphylococcus aureus Carriage
- Reduced Staphylococcus aureus Growth
- Reduced Staphylococcus aureus Viability
- Reduced Steroid Load
- Reduced Symptoms of Allergic Dermatitis
- Reduced Systemic Anaphylaxis
- Reduced Th-2 Cytokine Concentrations
- Reduced Th1/Th2 Ratio
- Reduced Th1/Th2 Ratio (IFN-γ/IL-4)
- Reduced Th17 Cell Level
- Reduced Th2 Cytokine Levels
- Reduced Th2 Cytokine Production
- Reduced Th2 Immunity
- Reduced Th2 Reactions
- Reduced Th2 Response
- Reduced Topical Corticosteroid Use
- Reduced Topical Drug Application
- Reduced Topical Steroid Usage
- Reduced Total IgE Levels
- Reduced Total Symptom Score
- Reduced Toxicity from Sodium Dodecyl Sulfate
- Reduced Transepidermal Water Loss
- Reduced Type 2 Immune Responses
- Reduced α-Lactalbumin-Specific IgE Level
- Reduced β-Lactoglobulin-Specific IgE Level
- Relapse Prevention in Atopic Dermatitis
- Restored Barrier Function
- Restored Microbial Balance
- Stabilized Skin Microbiome
- Stable Immune System Responses
- Unchanged Apple-Induced Symptoms
- Unchanged Immune Parameters